Results 151 to 160 of about 10,116 (169)

FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination. [PDF]

J Exp Clin Cancer Res
Qian Z, Jiang Y, Cai Y, Gao E, Wang C, Dong J, Wang F, Liu L, Wu D, Zhang F, Wang Y, Ning X, Li Q, You Y, Gu Y, Mei J, Zhao X, Zhang Y.   +17 more
europepmc   +1 more source

Combined Potential of Orlistat with Natural Sources and Their Bioactive Compounds Against Obesity: A Review. [PDF]

Molecules
Uuh Narvaez JJ, Chan Zapata I, Segura Campos MR.   +2 more
europepmc   +1 more source

Peer Review Report For: Effect of anti-obesity drug orlistat (Xenical™) on liver and kidney function in male rats fed a high-fat diet [version 1; peer review: 2 approved with reservations]

Jan Sobczyński
openalex   +1 more source

A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. [PDF]

Nat Med
McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Frühbeck G, Goossens GH, Monami M, Sbraccia P, Martinez-Tellez B, Woodward E, Yumuk V.   +11 more
europepmc   +1 more source

Tamarind-Derived Trypsin Inhibitor as a Potential Therapeutic Agent for Obesity: Evidence from In Vitro and Zebrafish Models. [PDF]

ACS Omega
de Sousa ALM, Serquiz RP, Luchiari AC, Figueiredo TC, Trajano AC, Oliveira E Silva EG, Serquiz AC, Lemos AEN, Dos Santos EA, Maia JKDS, de Araújo Morais AH.   +10 more
europepmc   +1 more source

Jämförelse av den viktminskande effekten och biverkningar av Orlistat och Liraglutid vid behandling av fetma

, 2018
Linnea Westling
openalex   +1 more source

Cycloastragenol Improves Fatty Acid Metabolism Through NHR-49/FAT-7 Suppression and Potent AAK-2 Activation in Caenorhabditis elegans Obesity Model. [PDF]

Int J Mol Sci
Mihaylova LV, Savova MS, Todorova MN, Tonova V, Binev BK, Georgiev MI.   +5 more
europepmc   +1 more source

The Obesity Drug Revolution: New Frontiers in Pharmacotherapy. [PDF]

Cureus
Manoria PC.
europepmc   +1 more source

Chylous Ascites From Cirrhosis-Related Portal Hypertension Treated With Medium-Chain Triglycerides, Octreotide, and Paracentesis. [PDF]

ACG Case Rep J
Clutario JDC, Velasquez CP, Chan SNL, Labio MED, Cruz AJD.   +4 more
europepmc   +1 more source